Key facts
- It has raised $14.9M; the latest was Early Stage VC in Feb 2025.
- Notable investors include Decent Capital, Bopu Asset, Forcefield Venture, IMO Ventures, Qian hai Fangyuan Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Meta Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Meta Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meta Pharmaceuticals
Developer of drugs intended to develop first-in-class medicines targeting immune cell metabolism for the treatment of chronic and autoimmune diseases. The company has been deeply engaged in the emerging field of immunometabolism to develop first-in-class original drugs in immunometabolism. The company also leverages AI + biomedical research to create a fast and reliable analytic and validation loop for new therapeutic targets and their mechanisms of action, accelerating target discovery and their translation into new therapeutics.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Employees
- 3
- Website
- metabiopharma.com/
- Ownership
- Privately Held (backing)
Meta Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meta Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meta Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.